wow...you put kblb in the same category as biotech companies that are strictly in the medical field?...
I just looked at the first 2 real quick...
intellia ip'd ONTO Nasdaq in 2016 at $22.00 per share, rasing $108 mil..
editas ipo'd in 2016 ONTO Nasdaq at $16.00 per share, rasing $94 mil..
now...explain to me how they compare in any way to a 20 cent otc company that has been a public company for ten years and now wants to do a 1/40 r/s to get themselves onto Nasdaq?...
theres just no comparison...you may as well have used tesla
And these companies get shorted by far more than anything else on the exchange. I was in one, ADXS that was so heavily shorted it destroyed the stock to pennies and caused a massive RS that failed miserably.